DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30455203.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2512.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy is standard in fit patients. Inactivating mutations of the nucleotide excision repair gene <i>ERCC2</i> can predict response to cisplatin-based chemotherapy. Evaluation of the functional impact of ERCC2 mutations can provide mechanistic frameworks supporting the potential predictive role of ERCC2 loss of function.<i>See related article by Li et al., p. 977</i>.
Medical subject headings
- Cisplatin
- Urinary Bladder Neoplasms